543 related articles for article (PubMed ID: 7967984)
1. Delayed-type hypersensitivity, mycobacterial vaccines and protective immunity.
Fine PE; Sterne JA; Pönnighaus JM; Rees RJ
Lancet; 1994 Nov; 344(8932):1245-9. PubMed ID: 7967984
[TBL] [Abstract][Full Text] [Related]
2. Vaccination and skin test studies on children living in villages with differing endemicity for leprosy and tuberculosis.
Ghazi Saidi K; Stanford JL; Stanford CA; Dowlati Y; Farshchi Y; Rook GA; Rees RJ
Int J Lepr Other Mycobact Dis; 1989 Mar; 57(1):45-53. PubMed ID: 2659701
[TBL] [Abstract][Full Text] [Related]
3. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Karonga Prevention Trial Group.
Lancet; 1996 Jul; 348(9019):17-24. PubMed ID: 8691924
[TBL] [Abstract][Full Text] [Related]
4. Gamma interferon responses induced by a panel of recombinant and purified mycobacterial antigens in healthy, non-mycobacterium bovis BCG-vaccinated Malawian young adults.
Black GF; Weir RE; Chaguluka SD; Warndorff D; Crampin AC; Mwaungulu L; Sichali L; Floyd S; Bliss L; Jarman E; Donovan L; Andersen P; Britton W; Hewinson G; Huygen K; Paulsen J; Singh M; Prestidge R; Fine PE; Dockrell HM
Clin Diagn Lab Immunol; 2003 Jul; 10(4):602-11. PubMed ID: 12853392
[TBL] [Abstract][Full Text] [Related]
5. The relationship between delayed type hypersensitivity and protective immunity induced by mycobacterial vaccines in man.
Fine PE; Pönnighaus JM; Maine NP
Lepr Rev; 1986 Dec; 57 Suppl 2():275-83. PubMed ID: 3553800
[No Abstract] [Full Text] [Related]
6. A strategy to improve the efficacy of vaccination against tuberculosis and leprosy.
Bretscher PA
Immunol Today; 1992 Sep; 13(9):342-5. PubMed ID: 1466750
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi.
Pönnighaus JM; Fine PE; Sterne JA; Wilson RJ; Msosa E; Gruer PJ; Jenkins PA; Lucas SB; Liomba NG; Bliss L
Lancet; 1992 Mar; 339(8794):636-9. PubMed ID: 1347338
[TBL] [Abstract][Full Text] [Related]
8. Delayed-type hypersensitivity to Mycobacterium leprae soluble antigens as a test for infection with the leprosy bacillus.
Sterne JA; Fine PE; Pönnighaus JM; Rees RJ; Chavula D
Int J Epidemiol; 1998 Aug; 27(4):713-21. PubMed ID: 9758130
[TBL] [Abstract][Full Text] [Related]
9. Does bacille Calmette-Guérin scar size have implications for protection against tuberculosis or leprosy?
Sterne JA; Fine PE; Pönnighaus JM; Sibanda F; Munthali M; Glynn JR
Tuber Lung Dis; 1996 Apr; 77(2):117-23. PubMed ID: 8762845
[TBL] [Abstract][Full Text] [Related]
10. The Karonga Prevention Trial: a leprosy and tuberculosis vaccine trial in northern Malaŵi. I. Methods of the vaccination phase.
Pönnighaus JM; Fine PE; Bliss L; Gruer PJ; Kapira-Mwamondwe B; Msosa E; Rees RJ; Clayton D; Pike MC; Sterne JA
Lepr Rev; 1993 Dec; 64(4):338-56. PubMed ID: 8127221
[TBL] [Abstract][Full Text] [Related]
11. rBCG30-induced immunity and cross-protection against Mycobacterium leprae challenge are enhanced by boosting with the Mycobacterium tuberculosis 30-kilodalton antigen 85B.
Gillis TP; Tullius MV; Horwitz MA
Infect Immun; 2014 Sep; 82(9):3900-9. PubMed ID: 25001602
[TBL] [Abstract][Full Text] [Related]
12. BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies.
Black GF; Weir RE; Floyd S; Bliss L; Warndorff DK; Crampin AC; Ngwira B; Sichali L; Nazareth B; Blackwell JM; Branson K; Chaguluka SD; Donovan L; Jarman E; King E; Fine PE; Dockrell HM
Lancet; 2002 Apr; 359(9315):1393-401. PubMed ID: 11978337
[TBL] [Abstract][Full Text] [Related]
13. Tuberculosis prevention: where do we go from here?
Warndorff DK
Afr Health; 1996 Nov; 19(1):21-2. PubMed ID: 12291917
[TBL] [Abstract][Full Text] [Related]
14. The cellular and molecular basis of immunity against mycobacterial diseases.
Colston MJ
Soc Appl Bacteriol Symp Ser; 1996; 25():33S-39S. PubMed ID: 8972118
[No Abstract] [Full Text] [Related]
15. Under-explored experimental topics related to integral mycobacterial vaccines for leprosy.
Gormus BJ; Meyers WM
Expert Rev Vaccines; 2003 Dec; 2(6):791-804. PubMed ID: 14711362
[TBL] [Abstract][Full Text] [Related]
16. The effect of BCG revaccination on all-cause mortality beyond infancy: 30-year follow-up of a population-based, double-blind, randomised placebo-controlled trial in Malawi.
Glynn JR; Dube A; Fielding K; Crampin AC; ; Kanjala C; Fine PEM
Lancet Infect Dis; 2021 Nov; 21(11):1590-1597. PubMed ID: 34237262
[TBL] [Abstract][Full Text] [Related]
17. Monocyte response receptors in BCG driven delayed type hypersensitivity to tuberculin.
Strapagiel D; Kasztalska K; Druszczyńska M; Kowalewicz-Kulbat M; Vrba A; Matusiak A; Chmiela M; Rudnicka W
Folia Histochem Cytobiol; 2008; 46(3):353-9. PubMed ID: 19056540
[TBL] [Abstract][Full Text] [Related]
18. Multiple skin testing of tuberculosis patients with a range of new tuberculins, and a comparison with leprosy and Mycobacterium ulcerans infection.
Shield MJ; Stanford JL; Paul RC; Carswell JW
J Hyg (Lond); 1977 Jun; 78(3):331-48. PubMed ID: 266538
[TBL] [Abstract][Full Text] [Related]
19. Environmental mycobacteria in northern Malawi: implications for the epidemiology of tuberculosis and leprosy.
Fine PE; Floyd S; Stanford JL; Nkhosa P; Kasunga A; Chaguluka S; Warndorff DK; Jenkins PA; Yates M; Ponnighaus JM
Epidemiol Infect; 2001 Jun; 126(3):379-87. PubMed ID: 11467795
[TBL] [Abstract][Full Text] [Related]
20. Vaccination and skin test studies on the children of leprosy patients.
Stanford JL; Stanford CA; Ghazi Saidi K; Dowlati Y; Weiss SF; Farshchi Y; Madlener F; Rees RJ
Int J Lepr Other Mycobact Dis; 1989 Mar; 57(1):38-44. PubMed ID: 2659700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
